Digital contraceptive techniques have been on the receiving end of bad press recently after Swedish company Natural Cycles was described as “misleading” by the UK’s advertising body, and a number of women complained about becoming pregnant while relying on the app.
But that hasn’t stopped the industry from thriving, with the launch of Moody Month, which tracks hormones and menstrual cycles , and Flo Health, an ovulation calculator, being valued at $200m in the same week, suggesting there is still massive demand among women for products which are invariably described as femtech.
Catering to a market that market analysts Frost & Sullivan have forecast will be worth $50bn by 2025, femtech is the subset of apps and gadgets geared at enhancing women’s wellbeing. Currently made up of at least 200 startups worldwide, the companies focus solely on women’s health and are primarily managed by female CEOs and innovators.
Woom, a fertility-tracking app that recently featured in Forbes’s list of 60 female-led startups, was started by Clelia Morales and Laurence Fontinoy, who left their jobs at eBay and Google respectively to launch the app after facing fertility issues themselves and raised £2mthrough crowdfunding.
“The app uses an algorithm to optimise pregnancy, but it’s also educating women about their bodies”, said the co-founders. “We wanted to fill the knowledge gap and to help women feel in control,” says Clelia, now a working mum of two. Apps in particular are favoured by women and girls who want to track their moods, hormones and cycles, simply to have a better understanding of their bodies.
Reproductiion is a major focal point for femtech, but the industry goes beyond that.
Kitty Croft, 15, from London, uses the period and ovulation tracking app, Clue, and says most of her friends do the same. They all use an in-app feature to sync their data, meaning everyone knows where their friend is in their cycle.
“To some this may seem slightly pointless, but to me it felt like a real shift in the way we see periods. People are embarrassed talking about periods, but this app makes them seem less of a shame and more of a way of life. It is a reminder that all women go through the same thing and no one should ever feel embarrassed about it. For my friends and I it is just another way for us to become closer, while also having a bit of a laugh.”
Other notable companies include Elvie, a device that strengthens the pelvic floor and who recently launched a cordless breast pump; Lia, a discreet, biodegradable pregnancy test; Hey Vina!, a female friendship-making app; and L, an ethical, female-targeted condom brand.
Developers in femtech are confident that the industry can help combat the dearth of women in scientific research, as well the social taboos around women’s health, from menstruation to postnatal depression and breastfeeding. Jacinda Ardern, the prime minster of New Zealand who returned to work six weeks after giving birth, recently described the wireless breast pump she uses at work as having “made it possible to do my job.”
But currently just 10% of global investment goes to female-led startups according to Forbes.
“It’s tough. 95% of the time you’re pitching to men who can’t relate to the product. Sometimes it’s uncomfortable,” says Woom’s Laurence, recalling a room of investors breaking into laughter at the mention of menopause. As women, “you have to show more [potential], more traction”, say the female founders. The duo also shared how people often assume they’re altruists running a social enterprise, joking: “You can’t just be women wanting to make money!”
Elvie’s co-founder, Tania Boler, says the femtech “boom” is finally changing the face of the women’s healthcare industry. “Until recently, consumer tech often just meant making a pink accessory or turning something into jewellery. Now there is the realisation that women appreciate and want the best technology available,” she says.
“While femtech started as a few niche companies solving women’s health issues it has added momentum to healthcare companies across the world, recognising the need for specialised solutions catering to women’s health,” says Shruthi Parakkal, a consultant at market analysts Frost & Sullivan.
This is why Portfolia, a US-based venture platform financed nearly exclusively by female investors, created the world’s first femtech fund in June. The fund is expecting to invest nearly $4m in six top-performing women’s wellness and health startups this year.
Earlier this year, the NHS partnered with Elvie to offer their pelvic trainer, which normally costs £169, on prescription to patients with stress urinary incontinence (SUI). The device is placed inside the vagina and connects to an app, which measures areas for improvements.
SUI is a common problem affecting an estimated one in three women and costs the NHS £233m every year. The majority of cases can be reduced or eliminated by pelvic floor muscle training. The biofeedback within the device is thought to improve both compliance and success rates by 10% as well as reduce surgery rates by 50%, potentially helping to save the NHS £424 per patient.
But femtech brands are not immune to the risks that befall any technological startup. Most notably, the Swedish-made contraceptive device Natural Cycles faced a backlash after several users became pregnant while using it and an advert describing the app a “highly accurate” method of birth control was found to be misleading by the Advertising Standards Agency. Meanwhile, whispers of elitism shroud products like Ava, the £249 hormone-mapping wristband . Many dislike the term femtech, seeing it as undermining an industry that caters to half the population.
“There is a popular concept that most of the femtech companies are focusing on very women-specific issues such as fertility, reproductive health or menstrual health. However, it is interesting to note that there is a high prevalence of chronic diseases among women – sometimes one to two times higher than that in men – like Alzheimer’s. There are several companies working towards making specialised solutions for women with such conditions based on their physiology and psychology,” said Parakkal.
“This kind of technology can increase accessibility to care, especially in developing countries and also rural areas – and especially for screening for chronic conditions, prenatal scans, cervical cancer screening etc. For example, cervical cancer screening in low-resource settings accounts for 80% of cervical cancer incidence and 95% of cervical cancer mortality.”
Heidi Darling of Portfolia says the growth in femtech is down to female investors making conscious choices to support the products. “This is the action part of the #MeToo movement,” she said. “We [women] know that money is power, and that we can put our money to good use … [and to companies that] are changing people’s lives.”